Compare QUIK & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QUIK | CGEN |
|---|---|---|
| Founded | 1988 | 1993 |
| Country | United States | Israel |
| Employees | 51 | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.1M | 201.8M |
| IPO Year | 1997 | 2001 |
| Metric | QUIK | CGEN |
|---|---|---|
| Price | $9.28 | $2.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $20.00 | $4.80 |
| AVG Volume (30 Days) | 181.0K | ★ 229.9K |
| Earning Date | 11-10-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $20,112,000.00 | N/A |
| Revenue This Year | $73.22 | N/A |
| Revenue Next Year | $18.40 | $55.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.28 | $1.43 |
| 52 Week High | $24.33 | $3.24 |
| Indicator | QUIK | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 50.14 | 49.52 |
| Support Level | $8.72 | $1.98 |
| Resistance Level | $10.14 | $2.33 |
| Average True Range (ATR) | 0.73 | 0.09 |
| MACD | 0.19 | 0.03 |
| Stochastic Oscillator | 75.97 | 73.68 |
QuickLogic Corp is a fabless semiconductor company developing programmable logic semiconductor technologies, including embedded Field Programmable Gate Array (eFPGA) intellectual property (IP) and specialized FPGA devices. Its product offerings include the eFPGA IP licensing business and associated professional services, as well as a range of FPGA silicon products, including EOS, ArcticLink III, PolarPro 3, PolarPro II, PolarPro, and Eclipse II products, among others. The company's customers come from various markets, including aerospace and defense, industrial and infrastructure systems, data processing and computing platforms, and certain embedded and edge computing applications. Geographically, it generates maximum revenue from North America and the rest from Asia Pacific and Europe.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.